×
About 4,645 results

ALLMedicine™ Hypokalemia Center

Research & Reviews  1,107 results

High prevalence of hypertension and target organ damage in patients with 11β-hydroxylas...
https://doi.org/10.1111/cen.14677
Clinical Endocrinology; Sun B, Lu L et. al.

Jan 25th, 2022 - Prevalence of hypertension and hypertension-mediated organ damage (HMOD) had not been well studied in patients with 11β-hydroxylase deficiency (11β-OHD). The study was to assess the prevalence and risk factors of hypertension and HMOD in patients ...

Hypokalemia in patients treated with intravenous flucloxacillin: incidence and risk fac...
https://doi.org/10.1111/bcp.15236
British Journal of Clinical Pharmacology; Leegwater E, Westgeest AC et. al.

Jan 22nd, 2022 - Hypokalemia is a potentially life-threatening adverse event of flucloxacillin with unknown incidence. The risk of flucloxacillin-induced hypokalemia has recently been suggested to be increased among females compared to males. The aim of this study...

Prognostic value of contralateral suppression for remission after surgery in patients w...
https://doi.org/10.1111/cen.14678
Clinical Endocrinology; Mørup S, Voss N et. al.

Jan 22nd, 2022 - Primary Aldosteronism (PA) is the most common cause of endocrine hypertension, and adrenalectomy is first line treatment for unilateral PA. Suppression of aldosterone secretion of the non-dominant adrenal gland at adrenal venous sampling (AVS), i....

Phenotypic Heterogeneity and Fertility Potential of Patients with 17-Hydroxylase/17,20-...
https://doi.org/10.1210/clinem/dgac029
The Journal of Clinical Endocrinology and Metabolism; Xu Y, Jiang S et. al.

Jan 20th, 2022 - 17α-Hydroxylase/17,20-lyase deficiency (17OHD) is caused by a human CYP17A1 gene mutation and has the classical phenotype of hypertension, hypokalemia, sexual infantilism, and primary amenorrhea in females (46,XX) and disorders of sexual developme...

Apparent mineralocorticoid excess: A diagnosis beyond classical causes of severe hypert...
https://doi.org/10.1097/MBP.0000000000000583
Blood Pressure Monitoring; Gulhan B, Ünsal Y et. al.

Jan 20th, 2022 - A genetic defect of 11 β-hydroxysteroid dehydrogenase causes apparent mineralocorticoid excess syndrome. Since 50 days of life, our patient was hospitalized several times for various reasons including hypokalemia. At the age of 3.3 years, she was ...

see more →

Guidelines  1 results

Case detection, diagnosis, and treatment of patients with primary aldosteronism: an end...
https://doi.org/10.1210/jc.2008-0104
The Journal of Clinical Endocrinology and Metabolism; Funder JW, Carey RM et. al.

Jun 17th, 2008 - Our objective was to develop clinical practice guidelines for the diagnosis and treatment of patients with primary aldosteronism. The Task Force comprised a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, si...

see more →

Drugs  502 results see all →

Clinicaltrials.gov  31 results

Application of 68Ga-Pentixafor PET/CT in Primary Aldosteronism and Pre-postoperative of SAAE
https://clinicaltrials.gov/ct2/show/NCT05188872

Jan 12th, 2022 - Primary aldosteronism: Hypertension is divided into primary hypertension and secondary hypertension. Secondary hypertension refers to hypertension with clear etiology. When the etiology is identified and effectively removed or controlled, hyperten...

Amiloride in Nephrotic Syndrome
https://clinicaltrials.gov/ct2/show/NCT05079789

Oct 15th, 2021 - The monocenter randomized-controlled AMILOR trial investigates the efficacy of the ENaC blocker amiloride in reducing edema in nephrotic syndrome compared with standard therapy with the loop diuretic furosemide. Patients with acute nephrotic syndr...

Epidemology of Acute Kidney Injury in Diabetic Patients Infected With covid_19 In Assiut University Hospital
https://clinicaltrials.gov/ct2/show/NCT05074797

Oct 12th, 2021 - Notably, in several studies, diabetes is one of the most reported comorbidities with poor prognosis in patients with severe COVID-19 due to Compromised innate immunity, pro-inflammatory cytokine reduced expression of ACE2 and use of renin-angioten...

Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease
https://clinicaltrials.gov/ct2/show/NCT03574363

Oct 4th, 2021 - The study will enroll up to 165 patients, randomized in a 1:1:1 ratio to 1 of 3 treatment groups (55 patients in each group): KBP-5074 0.25 mg once daily (QD), KBP-5074 0.5 mg QD, or placebo QD. Randomization will be stratified to balance enrollme...

Healthy Diet Rich in Potassium to Chronic Kidney Disease With Sodium Zirconium Cyclosilicate: A Feasibility Study
https://clinicaltrials.gov/ct2/show/NCT04207203

May 26th, 2021 - Feasibility, descriptive single arm open-label interventional trial lasting 6 weeks. The study will recruit 36 CKD patients at the outpatient clinic with: age between 18 to 85 years; glomerular filtration rate < 29 ml/min/1.73 m2 and not on dialys...

see more →

News  217 results

FDA Grants Breakthrough Therapy Designation to Patritumab Deruxtecan for EGFR+ NSCLC
https://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-patritumab-deruxtecan-for-egfr-nsclc

Dec 23rd, 2021 - The FDA has granted a breakthrough therapy designation to patritumab deruxtecan for the treatment of patients with metastatic or locally advanced EGFR-mutated non–small cell lung cancer (NSCLC) with disease progression on or after treatment with a...

FDA Approves Sirolimus Protein-Bound Particles for Malignant PEComa
https://www.onclive.com/view/fda-approves-sirolimus-protein-bound-particles-for-locally-advanced-unresectable-or-metastatic-pecoma

Nov 23rd, 2021 - The FDA has approved sirolimus albumin-bound particles for injectable suspension (Fyarro) for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor.1 The regulatory decision...

Monoclonal Antibody-Directed Therapies for the Management of Multiple Myeloma
https://www.onclive.com/view/monoclonal-antibody-directed-therapies-for-the-management-of-multiple-myeloma

Aug 17th, 2021 - Noa Biran, MD Myeloma Division John Theurer Cancer Center Hackensack University Medical Center The overall survival (OS) of patients with multiple myeloma (MM) has improved significantly over the past decade with the development of novel...

Ivosidenib/Azacitidine Significantly Improves EFS in Previously Untreated IDH1-Mutated AML
https://www.onclive.com/view/ivosidenib-azacitidine-significantly-improves-efs-in-previously-untreated-idh1-mutated-aml

Aug 2nd, 2021 - The combination of ivosidenib (Tibsovo) plus azacitidine significantly improved event-free survival (EFS) compared with azacitidine plus placebo in previously untreated patients with IDH1-mutated acute myeloid leukemia (AML), meeting the primary e...

Intravenous steroids for acute inflammatory bowel disease
https://www.mdedge.com/gihepnews/article/241590/ibd-intestinal-disorders/intravenous-steroids-acute-inflammatory-bowel

Jun 15th, 2021 - Key clinical point: Patients with an acute flare of inflammatory bowel disease (IBD) treated with intravenous methylprednisolone (IVMP) required significantly more rescue biologics or cyclosporine. Additionally, IVMP significantly reduced rates of.

see more →